Publications
Detailed Information
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Janne, Pasi A. | - |
dc.contributor.author | Baik, Christina | - |
dc.contributor.author | Su, Wu-Chou | - |
dc.contributor.author | Johnson, Melissa L. | - |
dc.contributor.author | Hayashi, Hidetoshi | - |
dc.contributor.author | Nishio, Makoto | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Koczywas, Marianna | - |
dc.contributor.author | Gold, Kathryn A. | - |
dc.contributor.author | Steuer, Conor E. | - |
dc.contributor.author | Murakami, Haruyasu | - |
dc.contributor.author | Yang, James Chih-Hsin | - |
dc.contributor.author | Kim, Sang-We | - |
dc.contributor.author | Vigliotti, Michele | - |
dc.contributor.author | Shi, Rong | - |
dc.contributor.author | Qi, Zhenhao | - |
dc.contributor.author | Qiu, Yang | - |
dc.contributor.author | Zhao, Lihui | - |
dc.contributor.author | Sternberg, David | - |
dc.contributor.author | Yu, Channing | - |
dc.contributor.author | Yu, Helena A. | - |
dc.date.accessioned | 2023-03-20T08:44:13Z | - |
dc.date.available | 2023-03-20T08:44:13Z | - |
dc.date.created | 2022-02-22 | - |
dc.date.created | 2022-02-22 | - |
dc.date.issued | 2022-01-01 | - |
dc.identifier.citation | Cancer Discovery, Vol.12 No.1, pp.74-89 | - |
dc.identifier.issn | 2159-8274 | - |
dc.identifier.uri | https://hdl.handle.net/10371/189482 | - |
dc.description.abstract | Receptor tyrosine-protein kinase ERBB3 (HER3) is expressed in most EGFR-mutated lung cancers but is not a known mechanism of resistance to EGFR inhibitors. HER3-DXd is an antibody-drug conjugate consisting of a HER3 antibody attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. This phase I, dose escalation/expansion study included patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) with prior EGFR tyrosine kinase inhibitor (TKI) therapy. Among 57 patients receiving HER3-DXd 5.6 mg/kg intravenously once every 3 weeks, the confirmed objective response rate by blinded independent central review (Response Evaluation Criteria in Solid Tumors v1.1) was 39% [95% confidence interval (CI), 26.0-52.4], and median progression-free survival was 8.2 (95% CI, 4.4-8.3) months. Responses were observed in patients with known and unknown EGFR TKI resistance mechanisms. Clinical activity was observed across a broad range of HER3 membrane expression. The most common grade >= 3 treatment-emergent adverse events were hematologic toxicities. HER3-DXd has clinical activity in EGFR TKI-resistant cancers independent of resistance mechanisms, providing an approach to treat a broad range of drug-resistant cancers. SIGNIFICANCE: In metastatic EGFR-mutated NSCLC, after disease progression on EGFR TKI therapy, treatment approaches include genotype-directed therapy targeting a known resistance mechanism or chemotherapy. HER3-DXd demonstrated clinical activity spanning known and unknown EGFR TKI resistance mechanisms. HER3-DXd could present a future treatment option agnostic to the EGFR TKI resistance mechanism. | - |
dc.language | 영어 | - |
dc.publisher | American Association for Cancer Research Inc. | - |
dc.title | Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer | - |
dc.type | Article | - |
dc.identifier.doi | 10.1158/2159-8290.CD-21-0715 | - |
dc.citation.journaltitle | Cancer Discovery | - |
dc.identifier.wosid | 000752491200001 | - |
dc.identifier.scopusid | 2-s2.0-85122457308 | - |
dc.citation.endpage | 89 | - |
dc.citation.number | 1 | - |
dc.citation.startpage | 74 | - |
dc.citation.volume | 12 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | TYROSINE KINASE INHIBITORS | - |
dc.subject.keywordPlus | ANTIBODY-DRUG CONJUGATE | - |
dc.subject.keywordPlus | TOPOISOMERASE-I INHIBITOR | - |
dc.subject.keywordPlus | DS-8201A | - |
dc.subject.keywordPlus | OSIMERTINIB | - |
dc.subject.keywordPlus | ADC | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.